These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 2076342)

  • 1. [Transdermal therapeutic system of scopolamine (TTS-S) in the prevention of sea sickness and its mechanism of action].
    Wang E
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1990 Oct; 25(5):299-302, 319. PubMed ID: 2076342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
    Nachum Z; Shupak A; Gordon CR
    Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histaminergic response to Coriolis stimulation: implication for transdermal scopolamine therapy of motion sickness.
    Wang ET; Zhou DR; He LH
    Aviat Space Environ Med; 1992 Jul; 63(7):579-82. PubMed ID: 1616432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention of motion sickness with a transdermal therapeutic system containing scopolamine. A randomized, comparative double-blind study in the German Federal Navy].
    Becker G; Goossens H; Seemann K; Souchon F; Weitz T
    Dtsch Med Wochenschr; 1984 Dec; 109(49):1881-5. PubMed ID: 6499689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of transdermal scopolamine on motion sickness during 7 days' exposure to heavy seas.
    van Marion WF; Bongaerts MC; Christiaanse JC; Hofkamp HG; van Ouwerkerk W
    Clin Pharmacol Ther; 1985 Sep; 38(3):301-5. PubMed ID: 4028625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of cinnarizine and transdermal scopolamine for the prevention of seasickness in naval crew: a double-blind, randomized, crossover study.
    Gil A; Nachum Z; Tal D; Shupak A
    Clin Neuropharmacol; 2012; 35(1):37-9. PubMed ID: 22139622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of transdermally administered scopolamine in preventing motion sickness.
    McCauley ME; Royal JW; Shaw JE; Schmitt LG
    Aviat Space Environ Med; 1979 Nov; 50(11):1108-11. PubMed ID: 393242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study on effect of acupoint sticker of TTS-ST93-1 in treating motion sickness].
    Pei J; Yang T; Liu Z
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 1998 Aug; 18(8):464-7. PubMed ID: 11477828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of TTS-scopolamine, dimenhydrinate, lidocaine, and tocainide on motion sickness, vertigo, and nystagmus.
    Pyykkö I; Padoan S; Schalén L; Lyttkens L; Magnusson M; Henriksson NG
    Aviat Space Environ Med; 1985 Aug; 56(8):777-82. PubMed ID: 3929760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy.
    Homick JL; Kohl RL; Reschke MF; Degioanni J; Cintron-Trevino NM
    Aviat Space Environ Med; 1983 Nov; 54(11):994-1000. PubMed ID: 6651736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo--a comparative study at sea.
    Noy S; Shapira S; Zilbiger A; Ribak J
    Aviat Space Environ Med; 1984 Nov; 55(11):1051-4. PubMed ID: 6508687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal scopolamine in the prevention of motion sickness at sea.
    Price NM; Schmitt LG; McGuire J; Shaw JE; Trobough G
    Clin Pharmacol Ther; 1981 Mar; 29(3):414-9. PubMed ID: 7009021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermally administered scopolamine vs. dimenhydrinate. I. Effect on nausea and vertigo in experimentally induced motion sickness.
    Pyykkö I; Schalén L; Jäntti V
    Acta Otolaryngol; 1985; 99(5-6):588-96. PubMed ID: 4024909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative in-flight study of a scopolamine-containing membrane plaster versus dimenhydrinate under defined acceleration conditions].
    Offenloch K; Zahner G; Dietlein G; Franz I
    Arzneimittelforschung; 1986 Sep; 36(9):1401-6. PubMed ID: 3539128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Transdermal scopolamine (TTS-scopolamine) for the prevention of postoperative nausea and vomiting].
    Tolksdorf W; Meisel R; Müller P; Bender HJ
    Anaesthesist; 1985 Dec; 34(12):656-62. PubMed ID: 4096357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transdermal scopolamine, oral meclizine, and placebo in motion sickness.
    Dahl E; Offer-Ohlsen D; Lillevold PE; Sandvik L
    Clin Pharmacol Ther; 1984 Jul; 36(1):116-20. PubMed ID: 6734040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevention of kinetosis in children. Transdermal therapy with scopolamine].
    Müller M; Besch W; Steilner D
    Fortschr Med; 1987 Feb; 105(4):82, 86-7. PubMed ID: 3557264
    [No Abstract]   [Full Text] [Related]  

  • 18. Reduction of salivary flow with Scopoderm TTS.
    Talmi YP; Finkelstein Y; Zohar Y; Laurian N
    Ann Otol Rhinol Laryngol; 1988; 97(2 Pt 1):128-30. PubMed ID: 3355042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scopolamine patch to prevent seasickness: clinical response vs. plasma concentration in sailors.
    Gil A; Nachum Z; Dachir S; Chapman S; Levy A; Shupak A; Adir Y; Tal D
    Aviat Space Environ Med; 2005 Aug; 76(8):766-70. PubMed ID: 16110693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scopolamine bioavailability in combined oral and transdermal delivery.
    Nachum Z; Shahal B; Shupak A; Spitzer O; Gonen A; Beiran I; Lavon H; Eynan M; Dachir S; Levy A
    J Pharmacol Exp Ther; 2001 Jan; 296(1):121-3. PubMed ID: 11123371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.